Industry: Medical Device

For all Expertise Items that belong to the Medical Device Industry

The Connected Device Journey

Join industry experts from Nelson LabsSterigenics, and Regulatory Compliance Associates (RCA) for a free, 3-day virtual symposium May 13-15 where we explore the full product lifecycle of connected and wearable medical devices. From R&D, product design to sterilization, regulatory approval, and launch — our experts will walk you through the key considerations that can make or break the successful launch of your connected device.


Click here to Learn More And Register


Day 1: From Concept to Clinical Trials

This day sets the foundation by exploring early-stage development and pre-clinical readiness for connected devices. Experts will discuss R&D strategies, packaging and sterilization selection, and regulatory requirements. 

Meeting Agenda (Please note, times listed below are in Eastern Time Zone)

11:00 AM – 12:00 PM So you think you’ve got a connected medical device? Development of a Connected Device

12:00 PM – 1:30 PM Packaging and Sterilization Modality Selection for Connected Devices

5-minute BREAK

1:35 PM – 2:05 PM Design Development Pitfalls in Connected Devices (30 min.)

2:05 – 3:05 PM Biocompatibility Evaluation, including a discussion on E&L for Medical Devices

3:05 – 3:30 PM 510(k) Marketing Submissions and Predetermined Change Control Plans

5-mintue BREAK

3:35 PM – 4:15 PM Live Q&A 

Register for Day 1


Day 2: Scaling for Production Success

This day focuses on production processes, quality management, and preparing for scalable manufacturing while ensuring regulatory compliance and most importantly, cybersecurity and data integrity.

Meeting Agenda

11:00 AM – 11:30 AM Does your Quality Management System have the right capabilities to ensure that your XBU Connect Device will be safe and effective?

11:30 AM – 12:30 PM Sterilization Process Design for Connected Devices

5-minute BREAK

12:35 PM – 1:35 PM Regulatory Requirements for Medical Device Cybersecurity by FDA’s CDRH and EU’s MDR & IVDR

1:35 PM – 2:35 PM Software Development for Connected Devices

2:35 PM – 3:05 PM Medical Device Data Integrity and Accessibility Concerns

5-minute BREAK

3:10 PM – 4:00 PM Live Q&A

Register for Day 2


Day 3: Sustaining Excellence Post-Approval

The final day tackles post-approval challenges, including crisis management, supplier oversight, and change management. 

Meeting Agenda

11:00 AM – 11:30 AM Common Submission Pitfalls and Best Practices

11:30 AM – 12:00 PM Supplier Quality Management Risks

12:00 PM – 12:30 PM Crisis Management and Recalls in Connected Devices

5-minute BREAK

12:35 – 1:35 PM Change Management  

1:35 – 2:35 PM Live Q&A

Register for Day 3

 

The new US Presidential Administration could bring significant impact on MedTech and pharmaceutical regulations for manufacturers and product developers. Join our expert panel of scientists and FDA consultants as they explore the potential regulatory changes. Speakers will discuss changes in several key areas, including FDA policy shifts, warning and consent letters, vaccine regulation, Artificial Intelligence in healthcare, and the supply chain. 

These experts will share firsthand knowledge of ongoing discussions and emerging trends, and help you prepare changes that will shape the future of the healthcare industry.

 

 

Attend this webinar and learn:

  • What regulatory changes could be coming in 2025
  • FDA focal points in the new administration
  • Potential impact to the MedTech and Pharm industries

 

 

Speakers:

Rona LeBlanc-Rivera, Ph.D.

Rona LeBlanc-Rivera, Ph.D. – Principle Consultant, Regulatory Affairs, Regulatory Compliance Associates

Rona has over 23 years of experience spanning the FDA and the pharmaceutical industry. She served as an FDA reviewer in chemistry, manufacturing and controls for biologics and generic drug applications, a regulatory affair professional, and as a pharmaceutical industry consultant, including support as primary liaison with FDA.


Anita Micheal

Anita Michael – Executive Principal Consultant, Pharma Compliance, Regulatory Compliance Associates

Anita has 24+ years of global regulatory and quality experience, including 16 years’ operating globally as a Pharmaceutical Expert, FDA Investigator and FDA Pre-Approval Manager. She specializes in preparation, remediation and designing of training for individuals at all levels of an organization.


Thor Rollins

Thor Rollins – Biocompatibility Expert, Nelson Labs

Thor Rollins is a certified microbiologist and specializes in the selection and conduct of in vitro and in vivo biocompatibility tests. He is a participating member of multiple committees and plays an active role along with the FDA in developing standards, discussing biocompatibility methods, and voting on changes.


Alpa Patel, M.S., RM (NRCM)

Alpa Patel, M.S., RM (NRCM) – Director of Lab Operations, Nelson Labs

Alpa Patel is a certified microbiologist and has been in the medical device industry for 20 years specializing in cleaning/disinfection and sterilization of reusable medical devices, endoscopes and validation of tissue disinfection or sterilization processes. She plays an active role with the FDA and regulatory committees in developing/changing current standards.

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

In this episode of RCA Radio®, host Brandon Miller is joined by Rod Mell, Executive Head – Life Science Consulting at RCA, as well as Jordan Elder, Director of Regulatory both at Regulatory Compliance Associates. We explore possible changes in the Medical Device industry in 2025 and provide you with insight on how to prepare yourself for these upcoming initiatives.

Listen in as we go over the updated EU MDR / EUDAMED timelines, recent and upcoming final guidance documents, the strategic priorities outlined by the FDA, the Quality Management System Regulation (QMSR Final Rule), the agency inspection focuses, and how companies can prepare themselves for success with the incoming changes.

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

This presentation provides a comprehensive overview of the FDA’s medical device pre-submission process, a critical step for manufacturers seeking to efficiently bring safe and effective devices to market. This session will examine the strategic advantages of utilizing the pre-submission program (Q-Sub), outlining key components and benefits.

Key takeaways will Include:

  • When to begin interfacing with FDA: Identify when your company should initiate the pre-submission process to maximize efficiency and reduce testing mistakes.
  • Maximizing your pre-submission interaction: Discover how to effectively prepare your submission and engage with the FDA to obtain valuable feedback on your device’s regulatory pathway, clinical trial design, and data requirements.
  • Common pitfalls and best practices: Gain insights into common mistakes to avoid and strategies to optimize your pre-submission experience for a smoother and faster FDA review process.
  • Real-world examples: Discuss how manufacturers have recently maximized their interactions with FDA or, in some cases, caused additional work to be required.   

This presentation is essential for medical device manufacturers, regulatory professionals, researchers, and anyone involved in developing and commercializing medical devices in the United States. Attendees will better understand how to leverage the pre-submission process to their advantage, ultimately accelerating their product’s journey to market.

Presenters:

Jordan Elder – Director, Regulatory Affairs, Regulatory Compliance Associates

Jordan has 15+ years of global regulatory comprehensive background in medical device regulations and a demonstrated history of successful product submissions including; FDA 510(k), EU Class IIa and IIb, Health Canada Class III, COFEPRIS Class III, and CFDA Class III submissions.


Anita Michael – Executive Principal Consultant, Pharma Compliance, Regulatory Compliance Associates

Anita has 24+ years of global regulatory and quality experience, including 16 years’ operating globally as a Pharmaceutical Expert, FDA Investigator and FDA Pre-Approval Manager. She specializes in preparation, remediation and designing of training for individuals at all levels of an organization.


Thor Rollins – Biocompatibility Expert, Nelson Labs

Thor Rollins is a certified microbiologist and specializes in the selection and conduct of in vitro and in vivo biocompatibility tests. He is a participating member of multiple committees and plays an active role along with the FDA in developing standards, discussing biocompatibility methods, and voting on changes.

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

 

Preparing a Clinical Evaluation for a CE Mark is no small task. Having it rejected by reviewers, and doing it over again to correct deficiencies is not uncommon. Clinical evaluations are commonly problematic for industry. Improving the preparation process starts with tips from recent submissions.

 

A clinical evaluation is the assessment and analysis of clinical data pertaining to a medical device to verify its clinical safety and performance. The EU MDR requirements for clinical evaluations are outlined in 2017/945, but some manufacturers don’t have history with the process. They could be facing challenges and rejections by the reviewers.

 

A clinical evaluation must be performed by device manufacturers pursuing the CE Mark prior to marketing the device in the European Union. Clinical evaluations are also repeated periodically as new clinical safety and performance information about the device is obtained.

 

The manufacturer demonstrates the device achieves its intended performance and that the risks and any adverse events are minimized and acceptable when weighed against the benefits. Claims made about the device’s performance and safety are supported by suitable evidence.

 

With regard to postmarket activities, manufacturers are expected to implement and maintain surveillance programs that routinely monitor the clinical performance and safety of the device as part of their quality management system (QMS). The QMS should use data generated from safety reports, including adverse event reports, results from published literature, any further clinical investigations, and formal post market surveillance studies.

 

Collecting Data

 

The literature review must be complete, covering pre- and postmarket data and any clinical investigations. In collecting data, it’s helpful to capture screen prints of searches, including the search terms and exact logic used in the search. Boolean logics such as “AND” and “OR” show repeatability and help the reviewers in analyzing the resulting clinical evaluation. For published and digital literature, it’s common for thousands of data sources to be identified.

 

Data Evaluation: The Heavy Lifting in Clinical Evaluations

 

After collecting the data, the next step is assessing the content and determining whether the data should be considered for the clinical evaluation.

 

regulatory complianceA scoring table can be useful for determining whether to include data. For example, data scored on factors such as device equivalency, application equivalency, similarity of operator, and demographic equivalency can be helpful during the analysis.

 

For studies that pass the scoring table, each must be summarized on how they support the essential requirements (see sidebar “The Clinical Evaluation Process”). A common mistake is simply copying the conclusion of the study instead of how it relates to the essential requirements.

 

Case Study: Class II device for breast biopsies

 

The manufacturer of the existing CE Mark device changed notified bodies. The new NB alerted the firm to numerous deficiencies in the clinical evaluation. The manufacturer decided it was beneficial to submit a new clinical evaluation.

 

The data collection resulted in 2211 papers. After an extensive analysis and scoring system, 27 papers were included in the clinical evaluation. A summary table was prepared for the clinical evaluation, which featured each paper and outlined the support of the essential requirements. The resulting clinical evaluation was approved without deficiency within 22 hours of submission.

 

Insights from the Experts

 

The clinical evaluation must be recreatable by third parties based on the process and scoring system outlined in the report. If the notified body can’t recreate it, they have no recourse except to find deficiency.

 

Make it easy for the CE Mark reviewers to check off each step. Highlight what they’re looking for relative to what you’re covering. Refer to guidances and standards that come from trusted industry sources.

 

Common errors can include the following:

  • Missing inclusion or exclusion criteria
  • Omitting applicable papers
  • Summarizing papers instead of evaluating them. Although a summary is required, the more important (and often omitted) portion is to explain how the data support the essential requirements
  • Forgetting summary tables
  • Forgetting a concluding argument. Explain how the document fulfills the requirements for the clinical evaluation.

 

Conclusion

 

Clinical evaluations include the assessment and analysis of the medical device’s clinical data to verify its clinical safety and performance. The stages are well-defined but can be intensive. A thorough clinical evaluation can involve thousands of data sources and significant time for proper assessment. Manufacturers should submit evaluations that are recreatable and make it easy for reviewers to follow.

 

 

regulatory compliance

Complete article published on Medical Device and Diagnostic Industry.

 

 

To begin the Regulatory Compliance Associates® scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. 

 

In this episode of RCA Radio, host Brandon Miller is joined by Nelson Labs Director of E&L Raymond Colton as well as board certified toxicologist Dr. Sarah Campbell also from Nelson Labs to discuss the recent draft FDA GUIDANCE DOCUMENT: Chemical Analysis for Biocompatibility Assessment of Medical Devices.

Listen in as we cover why this guidance why is important, the potential impacts of this guidance to device manufactures, and some best practices Nelson Labs testing facilities are already implementing to insure a smooth transition once this is published. We discuss things like changes to current chemical characterization approaches as possible leeway that could be given depending on the product.